Congress of the International Society on Thrombosis and Haemostasis

Abstract Index

A | B | C | D | E | F | G | H | I | J | K | L | M | N | O | P | Q | R | S | T | U | V | W | X | Y | Z

R
Radioisotopic synovectomy and haemophilic arthropathy in Asians: a retrospective study
Chew E. M. D., Tien S. L., Sundram F. X., Ho Y. K. L., Howe T. S.

rAHF-PFM development and quality assurance
Baker D.

Randomized trial of tinzaparin, a low molecular weight heparin (LMWH) vs. placebo in the treatment of mild-to-moderately active ulcerative colitis
Lassen M., Bloom S., Kiilerich S., O'Morain C., Forbes A., Orm S.

Randomized, double-blind comparison of ximelagatran, an oral direct thrombin inhibitor, and warfarin to prevent venous thromboembolism (VTE) after total knee replacement (TKR)
Francis C. W., Berkowitz S. D., Comp P. C., Lieberman J. R., Ginsberg J. S., Paiement G., Peters G. R., Roth A. W., Colwell Jr C. W.

Rapid analysis of the HindIII/intron 19 polymorphism within the human factor VIII gene by ARMS/PCR method
Azimifar B., Zeinali S., Nafissi N.

Rapid and automated quantification of the kinetics of thrombin formation using the Thrombin Dynamics Test (TDT)
Calatzis A., Reininger A. J., Spannagl A., Schramm W.

Rapid arterial thrombus formation after endothelial injury in streptozotocin-induced diabetic mice
Sommeijer D. W., Hansen H. R., Reitsama P. H., Ten Cate H.

Rapid induction of immune tolerance with von Willebrand factor containing factor VIII concentrate in acquired hemophilia A
Gerhardt A., Zotz R. B., Scharf R. E.

Rapid point-of-care assessment of enoxaparin activity during percutaneous coronary interventions: the ELECT study
Moliterno D., Hermiller J. B., Kottke-Marchant K., Kereiakes D. J., Kleiman N. S., Tcheng J. E.

Rapid screening of factor IX mutations by SSCP and sequencing in 50 Iranian families
Karimipour M., Zeinali S., Lak M., Safaie R., Nafissi N., Karimi M.

Rate of adverse events during OAT in patients with mechanical prosthetic heart valves replacement
Poli D., Antonucci E., Cecchi E., Betti I., Ilari I., Alessandrello Liotta A., Mannini L., Rogolino A., Abbate R., Prisco D.

Rates of recurrent thromboembolism and bleeding in venous thromboembolism patients treated with long-term LMWH
Burton E.C., Katona B.G., Peters G., Horrow J.C., Francis C.W.

Reactive oxygen species mediate cyclooxygenase-2 induction during monocyte transition into macrophages: critical role for NADPH oxidase
Barbieri S. S., Eligini S., Brambilla M., Tremoli E., Colli S.

Real-time imaging of the dynamics and secretary behavior of Weibel–Palade bodies
Van Mourik J., Romani De Wit T., Rondaij M. G., Hordijk P. L., Voorberg J.

Real-time visualization of platelet shape changes occurring in response to their adhesion on immobilized type I collagen or von willebrand factor under controlled blood flow conditions
Tamura N., Goto S., Ishida H., Tanabe T., Handa S.

Real-time whole-blood coagulation following ex vivo hemodilution with plasma substitutes: reversal of the coagulopathy by a fibrinogen concentrate
Fenger-Eriksen C., Heslop J., Anker-Møller E., Ingerslev J., Sorensen B.

Recognized and unrecognized clinical venous thromboembolism (VTE) after acute ischemic stroke (AIS): a prospective study using magnetic resonance direct thrombus imaging (MRDTI)
Kelly J. A., Lewis R. R., Rudd A., Moody A., Hunt B. J.

Recombinant activated coagulation factor VII for the treatment of spontaneous bleeding in a girl with inhibitors developed after autologus bone marrow transplantation
Dobaczewski G., Chybicka A., Toporski J.

Recombinant activated Factor VII (rFVIIa) for the treatment of bleeding secondary to acquired factor VIII inhibitor
Baudo F., Gaidano G. L., Carloni M. T., Coppola A., Iorio A., Marietta M., Marongiu F., Mazzucconi M. G., Miraglia E., Schiavoni M., Schinco P. C., Fariciotti A.

Recombinant activated factor VII (rFVIIa), as salvage treatment in the management of peri-operative intractable bleeding in cardiac surgery patients
Aggarwal A., Alcorn K.

Recombinant activated protein C (drotrecogin) is effective for purpura fulminans secondary to severe genetic protein C deficiency
Manco-Johnson M., Knapp-Clevenger R.

Recombinant Factor VIIa as hemostatic agent in acquired von Willebrand disease
Perez-Montes R., Arce O., Bermudez A., Yañez L., Sedano C., Zubizarreta A.

Recombinant factor VIIa in management of acute CNS and GI bleedings during warfarin thromboprophylaxis: clinical and biochemical aspects
Sorensen B., Johansen P., Neilsen G. L., Sorensen J. C., Ingerslev J.

Recombinant factor VIIa restores adhesion and aggregation of a IIbb 3-deficient platelets in vitro
Lisman T., Moschatsis S., Adelmeijer J., Nieuwenhuis H. K., De Groot P. G.

Recombinant factor VIIa reverses the anticoagulant effect of the long-acting pentasaccharide idraparinux in healthy volunteers
Bijsterveld N., Vink R., Van Aken B., Fennema H., Peters R. J. G., Meijers J. C. M., Buller H. R., Levi M.

Recombinant factor VIIa used to control massive hemorrhage during renal transplantation surgery; vascular graft remained patent
Dunkley S., Mackie F.

Recombinant factor VIII C1C2 domain expressed in E. coli
Hsu T.-C., Pratt K. P., Thompson A. R.

Recombinant FVIIa for the treatment of severe bleeding in patients with hematological malignancies and thrombocytopenia
Kotsi P., Katsarou O., Kouramba A., Gavalaki M., Kanellopoulou G., Tsourkala C., Markakis K., Karafoulidou A.

Recombinant FVIIa promotes adhesion and aggregation of platelets in normal subjects and von Willebrand disease patients as measured in the PFA100™
Tarantino M., Roberts J. C., Weber L. C., Caughey R. C., Tarantino M. D.

Recombinant FVIIa: correction of thrombocytopenic defects in whole blood clotting model
Yeo E., Miscevic N.

Recombinant human Factor XIII decreases gut ischemia reperfusion injury in the rat
Garcia R., Waggie K., Bishop P., Grossman A.

Recombinant Lopap (a prothrombin activator from Lonomia obliqua) has a very conservative structure of lipocalins
Reis C. V., Fritzen M., Ho P. L., Junqueira-De-Azevedo I. L. M., Schattner M., Chudzinski-Tavassi A. M.

Recombinant murine activated protein C is neuroprotective in a murine ischemic stroke model
Fernandez J. A., Xu X., Liu D., Zlokovic B. V., Griffin J. H.

Recombinant prolylcarboxypeptidase activates plasma prekallikrein
Shariat-Madar Z., Mahdi F., Schmaier A. H.

Recombinant proteins mimicking an integrin a2b1 cytoplasmic tail heterodimer
Kreis S., Kieffer N.

Recombinant PrPP102L stimulates t-PA mediated plasminogen activation 4-fold stronger than recombinant wild-type PrPc
Praus M., Epple G., Ziemer S., Gessner R.

Recombinant sendai virus-mediated intramuscular gene transfer of FGF-2 restores collateral blood perfusion of chronically ischemic rabbit hind limb, and inhibits neointimal hyperplasia of autologous femoral vein grafts
Tanii M., Yonemitsu Y. Y., Komori K. K., Shoji T. S., Maehara Y. M., Hasegawa M. H., Sueishi K. S.

Recombinant truncated tissue factor triggers coagulation in normal human plasma via the extrinsic pathway
Van Der Zee M., De Winter R. J., Nieuwland R., Ko Y., Sturk A., Hack C. E.

Recurrent pregnancy loss between the 8th and 15th week of gestation is not associated with an increased frequency of protein Z deficiency
Hopmeier P., Van Trotsenburg M., Dossenbach-Glaninger A.

Recurrent thrombosis in a young patient with a left-sided inferior vena cava and factor V Leiden and prothrombin 20210A
Boinot C., Christiaens L., Kitzis A., Allal J., Guicheteau M., Macchi L., Brizard A., Kraimps J. L.

Red blood cells ABH and Lewis antigens prevalence in von Willebrand disease patients
Zalepouchina O., Mineeva N., Papayan L., Andreeva T., Klimova N.

Reduced platelet sensitivity to nitric oxide donors in patients with a history of preeclampsia
Marietta M., Facchinetti F., Fazzio M., Pizzi C., Blasi I., Bertesi M., Cappi C., Pozzi S., Torelli G.

Reduced protein C and S activity and sickle cell disease severity
Schnog J., Meijer J., Duits A., Rojer R., Mac Gillavry M., Ten Cate H., Brandjes D.

Reduced sensitivity to aPC after fish oil supplementation via increased LDL and platelet microparticle formation
Englyst N. A., Byrne C. D.

Reducing body iron stores lowers inflammatory cytokine levels in atherosclerotic claudicants
Zacharski L. R., Depalma R. G., Hayes V. W., Cafferata T., May P. E., Mohammadpour H. A., Chow B. K., Hall M. R.

Reduction in stillbirth and IUGR with aspirin +/- low molecular weight heparin treatment in pregnancy
Everington T., Peebles D., Camilleri R., Maguire N., Cohen H.

Reference ranges for hemostatic parameters in children
Monagle P., Ignjatovic V., Barnes C., Newall F., Campbell J., Savoia H., Furmedge J.

Regulation of coagulation - the role of TAFI
Meijers J.C.M.

Regulation of coagulation factor VII expression in dermal fibroblasts by serum and growth factors
Wilcox J., Casanova J. R.

Regulation of connective tissue growth factor (CTGF) in synovial lining and modulation of the disease course of acute arthritis in an experimental model of rheumatoid arthritis by residues D793-P824 derived from thrombospondin-1-type 3 repeats
Manns J., Barbe M. F., Safadi F. F., Uknis A. B., Popoff S. N., De La Cadena R. A.

Regulation of gene expression in huvec and human umbilical progenitor CD 34⁺ cells by VEGF, bFGF and PPARg agonist
Dembinska-Kiec A., Polus A., Piatkowska E.

Regulation of GPVI-mediated platelet procoagulant response and degranulation
Appleby J. A., Farndale R. W., Goodall A. H.

Regulation of megakaryocyte polyploidization and platelet release by the cytoplasmic tail of glycoprotein Iba
Kanaji T., Russell S., Negrescue E., Fox J. E. B., Ware J.

Regulation of neovascularization by a-defensins: a link between inflammation and angiogenesis
Chavakis T., Rhee J. S., Liang O. D., Schubert U., Hammes H. P., Cines D. B., Preissner K. T., Bdeir K.

Regulation of plasminogen activation at the surfaces of mouse hepatocyte
Okada K., Ueshima S., Akao M., Seki T., Ariga T., Matsuo O.

Regulation of plasminogen gene expression by nerve growth factor (NGF)
Gutiérrez-Fernandéz A, Palmer R.J., Miles L.A.

Regulation of platelet procoagulant activity by collagen
Heemskerk J. W.

Regulation of tyrosine phosphatase SHP-1 in human platelets by protein kinase C
Jones M. L., Poole A. W.

Relapsing, recurrent and residual deep vein thrombosis
Girolami A.

Relation between circulating endothelial markers and anti-coagulation with different heparins in hemodialysis patients: a prospective study
Naumnik B., Borawski J., Mysliwiec M.

Relation between compliance and quality of treatment with vitamin K antagonists
Locadia M., Van Geest-Daalderop J. H. H., Sprangers M. A. G., Hutten B. A., Prins M. H.

Relation of changes in D-dimer and other coagulation markers with changes in Marder Score after treatment of acute venous thrombosis with the low molecular weight heparin Certoparin or unfractionated heparin
Harenberg J., Merx K., Tolle A. R., Huisman M. V.

Relation of prothrombotic platelet polymorphisms to the first manifestation of Coronary Artery Disease in middle-aged males
Mikkelsson J., Narhi L., Ihantola M., Ollikainen E., Eskola M., Pietila K., Nikus K., Niemela K., Karhunen P. J.

Relationship of the Val34Leu polymorphism in the factor XIII gene with venous thromboembolism in American whites and blacks: the GATE study
Dowling N. F., Hooper W. C., Dilley A., Lally C., Whitsett C., Ellingsen D., Evatt B. L., Austin H.

Relationship of thromboembolism (TE) to subsequent cancer diagnosis: a study in a veteran population
Saba H., Khalil F., Morelli G. A., Foulis P. R.

Release of chemokines by monocytes and endothelial cells upon exposure to Shiga toxin and LPS: potential roles in platelet activation
Guessous F., Heatherly D. P., Obrig T. G., Gear A. R. L.

Relevance of interindividual variability in d-dimer composition for comparison of assays
Kluft C., Meijer P.

Relevance of venographic distal thrombus assessment in venous thromboembolism (VTE) prophylaxis studies: lessons from the fondaparinux (Arixtra^®) database in major orthopedic surgery
Turpie A. G. G., Bauer K. A., Eriksson B. I., Lassen M. R.

Reliability of patient self-testing and point-of-care testing with the Harmony (TM) INR monitoring system: a 3-year study
Earp B., Steinmetz C., Jacoboson A. K., Ruybalid L., Howe B., Gunneman T., Peterson M., Buenjemia J.

Remnant-like lipoprotein particles potentiate platelet activation under high shear stress assessed by the ‘collagen column’, filled with collagen-coated small beads
Satoh K., Ohta M., Cuyun-Lira O., Kaneko M., Nakano T., Yatomi Y., Ozaki Y.

Removal of a BSE-derived agent by ion exchange chromatography used in the manufacture of a high purity factor VIII concentrate
Griffin B. D., Foster P. R., Bienek C., Macgregor I. R., Mcintosh R. V., Somerville R. A., Steele P. J., Reichl H. E.

Removing the bottleneck – automated detection of point mutations in the factor VIII gene by fluorescent sequence trace subtraction following high-throughput DNA sequencing
Keeney S., Watson P., Cumming A.

Renal disease among persons with hemophilia
Kulkarni R., Soucie M. J., Evatt B. L., Hemophilia Surveillance System & Project Investigators‡

Replacement therapy for surgery and delivery in three patients from a single family with R1374C type 2M von Willebrand disease (VWD): the role of PFA100 monitoring
Batlle J., Penas N., Perez A., Lourés E., Noya M. S., López-Fernández M. F.

Report from the studies on prevention: Extended travel
Caprini J. A., Maksimovic D., Sehgal L. R., Arcelus J. I.

Report of argatroban infusions for heparin-induced thrombocytopenia (HIT) diagnosed by functional assay in 2 congenital cardiac surgery patients, a neonate and a 5-month old
Boshkov L. K., Ibsen L., Kirby A., Ungerleider R., Shen I.

Reporting presence of 9 novel mutations in hemophilia B patients in Iran
Karimipour M., Zeinali S., Nasissi N., Lak M., Safaie R.

Repression of integrin a₁ gene (ITGA1) expression in human megakaryocytes coincides with DNA methylation of the core promoter
Kunicki T. J., Kanaji S., Jacquelin B., Rozenshteyn D.

Reproducibility of anticoagulation therapy control tested on fresh and frozen plasma
Karas G. K., Sturm D., Banovic M.

Residual platelet function can be detected in patients on antiplatelet therapy using novel Hemoscope reagents and standard Thrombelastograph^® (TEG^®)
Royle E., Diprose P., Gill R., Herbertson M., Boulton F., O'Shaughnessy D. O.

Resistance to fibrinolysis in arterial thrombi: the importance of platelets
Jones C. I., Gershlick A. H., Goodall A. H.

Resource utilization and loss of productivity during the 4 months following a diagnosis of deep venous thrombosis
Kahn S. R., Ducruet T., Johri M., Arsenault L., Desjardins L., Desmarais S., Joyal F., Kassis J., Lamping D., Miron M. J., Roussin A., Shrier I., Solymoss S.

Response to DDAVP in mild/moderate hemophilia A patients according to the underlying factor VIII genotype
D'Oiron R., Lavergne J. M., Peynet J., Jacquemin M., Oldenburg J., Guillet B., Rafowicz A., LAVEND'Homme R., Peerlinck K., Lambert T., Brackmann H., Saint-Remy J. M., Vermylen J., Schwaab R.

Results of clinical use of ‘NovoSeven’ in Russia
Kopylov K. G., Vdovin V. V., Andreeva T. A., Soskov G. I., Svirin P. V., Lopatina E. G., Plyusch O. P.

Results of d-dimer in the UK NEQAS (Blood Coagulation) proficiency testing program: Urgent need for improvements in Standardization of testing and reporting
Kitchen S., Jennings I., Kitchen D. P., Woods T. A. L., Preston F. E.

Resveratol and quercetin inhibit tissue factor expression in vascular cells by preventing IkappaBalpha degradation and c-Rel/p65 activation
Di Santo A., Napoleone E., Di Tommaso R., Donati M. B., De Gaetano G., Lorenzet R.

Resveratrol and trolox scavenge hydroxyl radicals produced in platelets activated by collagen
Dyr J. E., Vesela P., Scheiner T., Suttnar J., Dyr J. E., Vesela P., Scheiner T., Suttnar J.

Reteplase and direct thrombin inhibitors: concurrent use for acute thrombotic events in patients with heparin-induced thrombocytopenia
Sheikh M., Begelman S. M.

Retrospective analysis of heritable thrombophilia in 90 children with Legg-Perthes disease
Fernández De Velasco J., Llamas P., López-Franco M., Espinoza J., De Oña R., Gonzalez G., Espeldegui T., Marco I., De Lucas J. C., Tomás J. F.

Retrospective study of acquired factor VIII inhibitor
Rodríguez I., Díaz A., Bentancor N., Pierri S., Otero A., Arago A.

Reversal of ADP-induced aggregation in human heparinized plasma (HPRP), a model system for study of platelets which have been exposed to different degree of activation in vivo and means of modulating their response
Murer E.

Reversal of low molecular weight heparin (LMWH) prior to invasive procedures using subcutaneous unfractionated heparin in children with an ongoing high risk for thrombosis
Bauman M., Chan A. K., Mitchell L., Massicotte M. P.

Reversal of warfarin or low molecular weight heparin (LMWH) using subcutaneous unfractionated heparin (UFH) in pediatric outpatients with an ongoing high risk for thrombosis and requiring invasive procedures: a prospective cohort study of 146 children
Bauman M., Chan A. K., Mitchell L., de Veber G., Massicotte M. P.

Reversible inactivation of anti-plasmin: evidence for a latent conformation
Wang H., Pap S., Wiman B.

Reviparin normalizes tissue factor pathway activation in patients with lower limb immobilization and is not associated with heparin antibody production
Kaiser P., Prechel M., Hoppensteadt D., Bacher P., Misselwitz F., Lassen M. R., Walenga J. M.

Revisiting human plasma-derived factor VIII
Shanbrom E., Owens W.

rFVIIa (Novoseven^®) in the treatment of Glanzmann's Thrombastenia
Antunes M., Sousa Mendes D., Dominguez C., Nogueiras T., Dias M., Diniz M. J.

rFVIIa NovoSeven^®– Hemostatic agent not only for hemophiliacs
Blatny J., Bulikova A., Penka M., Slechtova M., Smejkal P., Magnova O., Sterba J.

Risk assessment of venous thromboembolism in pregnant women with factor V Leiden, prothrombin 20210 A mutation, elevated factor VIII levels or mild hyperhomocystinaemia
Van De Poel M., Libourel E. J., Bank I., Middeldorp S., Koopman M. M. W., Hamulyak K., Van Pampus E. C. M., Prins M. H., Buller H. R., Van Der Meer J.

Risk factors and long-term follow-up of patients with the immune type of heparin induced thrombocytopenia
Gerdsen F., Wenning B., Bauersachs R., Lindhoff-Last E.

Risk factors for carotid artery plaque formation in premenopausal women with systemic lupus erythematosus
Hampton K., Sheli N., Brookfield C., Ashurst H., Akil M., Snaith M.

Risk factors for recurrent venous thrombosis: a prospective follow-up of the Leiden thrombophilia study (LETS)
Christiansen S., Koster T., Vandenbroucke J. P., Rosendaal F. R.

Risk factors for venous thromboembolism in chronically bedridden patients admitted to the Hospice Unit
Scannapieco G., Rossi M., Baldessin F., Rattazzi M., Pavan P., Villalta S., Pauletto P.

Risk factors of major hemorrhages during treatment of acute DVT: results from 5 randomized trials
Mismetti P., Yeguiayan J. M., Quenet S., Tardy B., Decousus H.

Risk factors. Fibrinogen vs. Lipoproteins: a new view
Weinstock N.

Risk for recurrent venous thromboembolism after a first superficial vein thrombosis among carriers of inherited thrombophilia
De Stefano V., Rossi E., D'Orazio A., Za T., Leone G.

Risk for recurrent venous thromboembolism among patients with severe inherited thrombophilia
De Stefano V., Martenelli I., Legani C., Rossi E., Grandone E., Castaman G., Palareti G., Mannucci P. M., Leone G.

Risk for venous thromboembolism among younger or older carriers of inherited thrombophilia
De Stefano V., Rossi E., D'Orazio A., Za T., Leone G.

Risk for venous thrombosis in unusual sites associated with inherited thrombophilia: analysis of 133 patients
De Stefano V., Rossi E., D'Orazio A., Za T., Leone T.

Risk of ischemic stroke (IS) associated with plasma levels of thrombin-activatable inhibtor fibrinolysis (TAFI)
Santamaria A., Oliver A., Borrel M., Ortin R., Belvis R., Marti-Fabregas A., Forner R., Mateo J., Fontcuberta J.

Risk of pregnancy-related venous thromboembolism (VTE) in 60 hereditary AT-deficient women from 45 families: study of 164 pregnancies
Conard J., Mathieux V., Horellou M. H., Elalamy I., Samama M. M.

Risk of recurrence of cerebral venous and sinus thrombosis, influence of treatment
Gosk-Bierska I., Mcbane R. D., Karnicki K., Wysokinski W. E.

Risk of recurrence of venous thromboembolism (VTE) and high factor VIII plasma levels
Legnani C., Cini M., Poggi M., Cosmi B., Coccheri S., Palareti G.

Risk of recurrent thrombotic events in patients with coronary heart disease and left ventricular dysfunction
De Lorenzo F., Xiao H. B., Kadziola Z., Kakkar V. V.

Risk of venous thromboembolism after air travel: interaction with thrombophilia and oral contraceptives
Battaglioli T.

Risk of venous thromboembolism during pregnancy and puerperium in women with homozygous form of F V Leiden
Dulicek P., Slechtova M., Maly J., Bulikova A., Beranek M., Penka M., Pacejka M.

Risk of venous thrombosis for patients with various malignancies and with factor V Leiden or the prothrombin 20210 A mutation: the MEGA case–control study
Blom J. W., Doggen C. J. M., Rosendaal F. R.

Rituximab – a challenge for the therapy of inhibitors to factor VIII
Krause M., Betz C., Scharrer I., Krause M.

Rituximab reduces anti-phospholipid antibody (APA) titers and improves hypercoagulability in patients with anti-phospholipid syndrome (APS)
Yamazaki M., Kaneda M., Ito T., Ontachi Y., Mizutani T., Morishita E., Asakura H., Kawashima Y., Nakao S.

Role of Anti-thrombin residue Glu381 (P13)
Johnson D. J. D., Huntington J. A.

Role of basic residues of proexosite 1 on prothrombin in the prothrombinase complex
Yang L., Manithody C., Rezaie A. R.

Role of Blood–Borne Tissue Factor in Thrombus Propagation
Nemerson Y.

Role of cardiac myocyte tissue factor in hemostasis in the heart
Pedersen B., Pawlinski R., Tencati M., Mackman N.

Role of factor IX surface loop 342–347 in factor VIII-mediated enhancement of catalytic activity
Rohlena J., Kolkman J. A., Fribourg C., Lenting P. J., Mertens K.

Role of genetic factors in vascular access thrombosis
Özbek N., Ataç B., Özdemir N., Verdi H., Haberal M.

Role of NADPH oxidase on mechanisms implicated in anoxia/reoxygenation-induced leukocyte adhesion to HUVECs
Paysant J., Rupin A., Sansilvestri-Morel P., Lembrez N., Verbeuren T. J.

Role of PI 3-kinase in glycoprotein VI-dependent calcium signaling in human platelets
Munnix I., Van Montfoort A. P. A., Farndale R. W., Heemskerk J. W. M., Sage S. O.

Role of platelet-leukocyte–endothelium interactions in neointimal hyperplasia
Clerin V., Espindle A., Erickson J., Shaw G. D., Schaub R. G., Kumar A.

Role of polymorphonuclear (PMN) leukocyte activation in the formation of PMN-platelet aggregates in Essential Thrombocythemia (ET) and Polycythemia Vera (PV)
Falanga A., Marchetti M., Bettarello G., Vignoli A., Balducci D., Barbui T.

Role of protein C system in the advancement of activation zone of coagulation: A two-dimensional mathematical model
Barynin Y. A., Vystavkin A., Khanin M. A.

Role of pulmonary inflammation on the peripheral thrombotic risk following intratracheal instillation of diesel exhaust particles
Nemmar A., Nemery B., Hoet P. H. M., Vermylen J., Hoylaerts M.

Role Of SLP-76 and SYK signaling for separation of blood and lymphatic vascular networks
Kahn M.

Role of surface amino acid residues in thrombin essential for inhibition by antithrombin, heparin cofactor II and protein C inhibitor
Fortenberry Y., Ly L., Myles T., Leung L. L. K., Whinna H. C., Church F. C.

Role of the affinity state of the a IIbb 3 receptor for fibrinogen in the formation and reversibility of model particle and platelet aggregation in shear
Frojmovic M., Bonnefoy A., Labarthe B., Legrand C.

Role of the FcR gamma chain in collagen-induced platelet procoagulant activity
Lentz S., Leo L., Eastvold J. S., Di Paola J.

Role of the Gla and first EGF-like domains of Factor X in the Prothrombinase and Tissue Factor-Factor VIIa complexes
Thiec F., Cherel G., Christophe O. D.

Role of the tissue factor-thrombin pathway in endotoxemia
Pawlinski R., Pedersen B., Mackman N.

Role of the Type Ia PI 3-kinase p110beta isoform in integrin alpha(IIb)beta(3) bi-directional signaling
Schoenwaelder S. M., Mulchandani M., Yap C., Kulkarni S., Hughan S. C., Salem H. H., Jackson S. P.

Role of two populations of thrombocytes in arterial thrombosis in zebrafish
Jagadeeswaran P., Gregory M., Thattaliyath B. D.

Roles of autolytic loop-2 and at Asp⁵⁵⁴ of human prothrombin in the specificity of meizothrombin
Koike H., Morita T.

Roles of low specificity and cofactor interaction sites on thrombin during factor XIII activation: competition for cofactor sites on thrombin determines its fate
Philippou H., Rance J., Myles T., Hall S. W., Ariens R. A. S., Grant P. J., Leung L., Lane D. A.

Roles of the individual g-carboxyglutamic acid residues of factor VII
Nagaizumi K., Inaba H., Suzuki T., Amano K., Arai M., Fukutake K.

ROTEG thromboelastography: sample stability and results in warfarinized and heparinized patients
Woolley A. M., Hunter A., Hampton K. K., Makris M., Kitchen S.

Routine coagulation screening to predict surgical bleeding is frequently misleading, of no significant clinical value and should be abandoned: results of a systematic review
Chee Y., Greaves M.

Routine homocysteine monitoring: stabilization of blood samples with fluoride
Luxembourg B., Bauersachs R., Gerdsen F., Rüfer A., Lindhoff-Last E.

Ryudocan (syndecan-4) deficiency increases susceptibility to LPS-induced shock in mice
Kojima T., Ishiguro K., Takagi A., Iwase M., Adachi T., Hayashi M., Takeshita K., Yamamoto K., Matsushita T., Saito H.